A combination of anti-DR5, anti-CD40, and anti-CD137 agonistic antibodies aiming to induce apoptosis in tumor cells, activate antigen presenting cells (innate immunity), and co-stimulate CD8+ T cells (adaptive immunity), respectively, has been shown to eradicate both established transplantable and spontaneous tumors (10). This evidence concerns the gene CD8A and neoplasm.